The basis for treatment in multiple sclerosis - PubMed

Review

The basis for treatment in multiple sclerosis

A Compston. Acta Neurol Scand Suppl. 2006.

Abstract

Contemporary licensed treatments for multiple sclerosis fail to provide a solution for the disease because their effects are limited to a modest reduction in the frequency of new episodes. They do not reduce disability or materially influence the progressive phase of the disease. A contemporary strategy for management requires a more detailed analysis of the separate contributions to the clinical features and overall course made by inflammation, axonal injury, compensatory mechanisms, and remyelination. From this formulation emerges the need either for early and fully effective suppression of the inflammatory response, limiting the damage to all components of the axon-glial unit; or the development of strategies for axonal and myelin repair that solve the issues of controlled differentiation, delivery and timing of these cell and growth factor-based interventions.

Similar articles

• Axonal damage in multiple sclerosis: a complex issue in a complex disease.

  Grigoriadis N, Ben-Hur T, Karussis D, Milonas I. Grigoriadis N, et al. Clin Neurol Neurosurg. 2004 Jun;106(3):211-7. doi: 10.1016/j.clineuro.2004.02.017. Clin Neurol Neurosurg. 2004. PMID: 15177770 Review.

• The pathogenesis and basis for treatment in multiple sclerosis.

  Compston A. Compston A. Clin Neurol Neurosurg. 2004 Jun;106(3):246-8. doi: 10.1016/j.clineuro.2004.02.007. Clin Neurol Neurosurg. 2004. PMID: 15177777

• [Multiple sclerosis: role of growth factors and remyelination].

  Lubetzki C. Lubetzki C. Presse Med. 1994 Nov 5;23(34):1577-81. Presse Med. 1994. PMID: 7824494 Review. French.

• Timing of Future Remyelination Therapies and Their Potential to Stop Multiple Sclerosis Progression.

  Zeydan B, Rodriguez M, Kantarci OH. Zeydan B, et al. Adv Exp Med Biol. 2017;958:161-170. doi: 10.1007/978-3-319-47861-6_10. Adv Exp Med Biol. 2017. PMID: 28093713

• Remyelination of the central nervous system.

  Compston A. Compston A. Mult Scler. 1996 Jul;1(6):388-92. doi: 10.1177/135245859600100622. Mult Scler. 1996. PMID: 9345424

Cited by

• Tracking the evolution of CNS remyelinating lesion in mice with neutral red dye.

  Baydyuk M, Cha DS, Hu J, Yamazaki R, Miller EM, Smith VN, Kelly KA, Huang JK. Baydyuk M, et al. Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14290-14299. doi: 10.1073/pnas.1819343116. Epub 2019 Jun 24. Proc Natl Acad Sci U S A. 2019. PMID: 31235582 Free PMC article.

• HSV Recombinant Vectors for Gene Therapy.

  Manservigi R, Argnani R, Marconi P. Manservigi R, et al. Open Virol J. 2010 Jun 18;4:123-56. doi: 10.2174/1874357901004030123. Open Virol J. 2010. PMID: 20835362 Free PMC article.

• Transplantation of Induced Pluripotent Stem Cell-Derived Neural Stem Cells Mediate Functional Recovery Following Thoracic Spinal Cord Injury Through Remyelination of Axons.

  Salewski RP, Mitchell RA, Li L, Shen C, Milekovskaia M, Nagy A, Fehlings MG. Salewski RP, et al. Stem Cells Transl Med. 2015 Jul;4(7):743-54. doi: 10.5966/sctm.2014-0236. Epub 2015 May 15. Stem Cells Transl Med. 2015. PMID: 25979861 Free PMC article.

• Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.

  Rodgers JM, Robinson AP, Miller SD. Rodgers JM, et al. Discov Med. 2013 Aug;16(86):53-63. Discov Med. 2013. PMID: 23911232 Free PMC article. Review.

• Statin therapy and multiple sclerosis disability in a population-based cohort.

  Paz Soldán MM, Pittock SJ, Weigand SD, Yawn BP, Rodriguez M. Paz Soldán MM, et al. Mult Scler. 2012 Mar;18(3):358-63. doi: 10.1177/1352458511421920. Epub 2011 Sep 9. Mult Scler. 2012. PMID: 21908483 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Medical

  • MedlinePlus Health Information